



Biocept Inc.
Investor Relations Department
5810 Nancy Ridge Drive
San Diego, CA 92121
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: BIOC

Last Trade:	0.74
Trade Time:	4:00 PM ET Dec 8, 2017
Change:	-0.01 (-0.831%)
Day Range	0.71 - 0.76
52-Week Range	0.60 - 3.39
Volume	729,605

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company leverages its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. Biocept's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests perfor... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Dec 6, 2017*
[Biocept Announces Pricing of Public Offering of up to 4,925,936 Shares of Common Stock](#)
- Dec 5, 2017*
[First U.S. Patent Issued for Biocept's Target Selector Oncogene Mutation Enrichment and Detection Liquid Biopsy ctDNA Platform](#)
- Nov 28, 2017*
[Biocept and UC San Diego Medical Center Announce Clinical Study Collaboration to Demonstrate Utility of Biocept's Liquid Biopsy Test in Immunotherapy](#)
- Nov 9, 2017*
[Biocept Reports Third Quarter 2017 Financial Results](#)
- Nov 2, 2017*
[Biocept to Release Third Quarter Financial Results and Host Investor Conference Call on November 9, 2017](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 28, 2017*
[Annual Report \(10-K\)](#)
- Mar 30, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 14, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 14, 2017*
[Quarterly Report \(10-Q\)](#)
- May 15, 2017*
[Quarterly Report \(10-Q\)](#)